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Vascular cognitive disorders (VCDs) are a heterogeneous
group of neurocognitive disorders with the salient feature
being that cognitive decline is primarily attributable to cere-
brovascular disease. The term VCD has a chequered history,
and it includes not only vascular dementia (VaD; e.g., post-
stroke and multi-infarct dementia), but also cognitive
impairment of vascular origin that does not meet the criteria
for dementia. VaD is common and is generally considered to
be the second most common form of dementia, after
Alzheimer’s disease (AD) [1].
The prevalence and incidence of VCD varies depending
on the diagnostic criteria applied and the populations studied.
In 11 population-based European studies conducted in the
1990s, the age-standardized prevalence of VaD was esti-
mated to be 1.6% compared to 4.4% for AD [2]; the preva-lence of VaD was 0.3% in the age group 65–69 years and
5.2% in those aged 90 and above, and VaD accounted for
15.8% of all dementias in these studies [2]. The Canadian
Study of Health and Aging used a broader concept termed
vascular cognitive impairment (VCI) which consisted of
three subgroups: VCI with no dementia, VaD, and AD with
a vascular component. The authors estimated that approxi-
mately 5% of people over the age of 65 years had VCI,
with 2.4% having VCI with no dementia, 0.9% havingmixed
(vascular and neurodegenerative) dementia and 1.5% having
VaD [3]. Various clinical studies have shown that the preva-
lence of dementia is much greater in post-stroke patients,
with 6 to 32% being reported as having dementia three
months after stroke [3–8]. A systematic review reported
that dementia is 3.5 to 5.6 fold more frequent in patients
with stroke than in stroke-free controls [9]. Because risk fac-
tors for stroke are modifiable, and its incidence has been
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be regarded as a powerful and modifiable risk factor for de-
mentia [10].
Poststroke dementia has emerged as an important subset of
VCD primarily because of the large impact stroke has on the
risk of VCD. The cognitive consequences of stroke as well as
the associated burden of increased functional dependency, insti-
tutionalization, andmortality rates are increasinglybeing recog-
nized [11]. However, many aspects of poststroke dementia are
uncertain [5], and the precise impact of a stroke on pre-
existing cognitive impairment has been disputed. Patients
with stroke usually have a complex combination of large and
small vessel disease in the brain; in older patients in particular,
nonvascular pathology such as AD may also be present [12].
Some studies found that up to 10% of stroke patients have
cognitive impairment that couldbeclassifiedasdementiabefore
their first stroke [4,5,8], a finding that may be attributable to
previous silent infarcts, noninfarct small vessel disease or AD
pathology, or a combination of these. An American case-
control longitudinal study reported that a stroke doubles the
risk of dementia, that this excess risk diminishes with time,
and that it does not apply to those .85 years [13]. According
to a recent systematic review and meta-analysis, about one-
tenth of patients develop new dementia soon after first stroke,
and over one-third are demented after a recurrent stroke [8].
Although older age and low levels of education have
consistently emerged as key predictors of worse cognitive
outcome soon after stroke [8,14], studies have shown
inconsistent findings in relation to other risk factors, which
include cerebrovascular disease risk factors such as
diabetes mellitus and atrial fibrillation, prior pathology,
stroke features, and infarct characteristics [8,9,15].
Making better use of existing data to improve stroke and
dementia prevention and treatment is a priority for many
governments and funders. The Joint Program for Neurode-
generation (JPND) thus recently funded several initiatives
to improve data usage. Metacohorts is one of these initiatives
focused on vascular contributions to dementia and the group
identified over 90 studies, including over 600,000 subjects
worldwide that included data relevant to vascular effects
on neurodegeneration including cognitive consequences of
stroke [16].
Stroke and Cognition consortium (STROKOG) is a
recently established consortium of prospective post-stroke/
TIA studies from around the world, including, at the time
of writing, 25 studies with up to 12,092 patients from 16
countries and 25 institutions worldwide. By harmonizing
data and conducting individual participant data (IPD)
meta-analyses on studies from around the world, STRO-
KOG aims to better understand the longitudinal course of
poststroke cognitive impairment and investigate differences
in the prevalence of VCD as well as risk and protective fac-
tors between different countries and ethnic groups. In IPD
meta-analysis, the original research data are sought directly
from the researchers responsible for each study rather
than extracting summary (aggregate) data from studypublications or from investigators. The original data can
then be re-analyzed centrally and combined, if appropriate,
in meta-analyses. There are various advantages of con-
ducting IPD meta-analyses over standard meta-analysis,
such as the ability to investigate patient level characteristics,
adjust for the same confounding factors across studies,
address new research questions, and reduce publication
bias [17,18]. By harmonizing and conducting analyses on
a rich collection of individual participant data, STROKOG
can examine risk factors on the patient level and apply
standardized methods of statistical analyses and dementia
diagnosis that could produce more accurate prevalence
estimates and more detailed information on the risk
factors for VCD and the impact stroke has on cognitive
decline. It is anticipated that the findings of STROKOG
will help guide and optimize preventative strategies and
health policy worldwide. STROKOG was officially
established at the VASCOG (Society for the Study of
Vascular Cognitive and Behavioral Disorders) 2015
meeting in Tokyo, Japan.2. Methods
2.1. Membership
Studies are eligible to participate in STROKOG if they
meet the following membership criteria:
1. Prospectively recruited patients with stroke, TIA, or
high-stroke risk (such as patients with atrial fibrilla-
tion, hypertension, genetic disorders such as CADA-
SIL and so forth).
2. Are longitudinal, with a minimum of two waves of as-
sessments conducted or planned.
3. Have a minimum sample size of 75.
4. The major outcome measures include dementia and/or
cognitive impairment and/or cognitive decline.
Official enrollment requires the study lead investigator to
sign a memorandum of understanding (MoU) which spec-
ifies a willingness to share nonidentifiable data for joint an-
alyses. Studies that have restrictions on data use and data
sharing may also participate in STROKOG by conducting
in-house analyses using STROKOG protocols and providing
summary data for pooling.
At the time of writing, there are 24 officially enrolled
member studies of STROKOG and one unofficial member
study which plan to obtain participants’ permission to share
data before signing the MoU. These studies and their key
demographic characteristics are shown in Table 1.
Supplementary Table S1 shows some salient findings from
each member study. They represent 16 different countries,
including one lower middle income country from across
five continents (Africa, Asia, Australia, Europe, and North
America). In total, there are 12,092 participants, and for
most studies, patients were recruited consecutively as they
were admitted to hospital with a recent stroke.
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a recent TIA, and those with a previous stroke were typically
not excluded. The longest follow-up duration of the studies
is 21 years and the median is 3 years. Table 2 shows the list of
neuropsychological tests used in each study.
2.2. Organization
The STROKOG Research Steering Committee (RSC)
consists of a representative from each of the contributing
studies, generally the lead investigator or a delegate. The pri-
mary functions of the RSC are to
1. Develop guidelines for the inclusion and exclusion of
studies.
2. Provide rules of participation and guidelines for the
roles and responsibilities of the participating studies.
3. Approve Work Groups (see research projects below).
4. Select topics of interest.
5. Provide overall analytic strategies.
6. Develop rules for publication, including authorship.
7. Develop rules for the protection of intellectual prop-
erty, when relevant.
8. Seek funds to support STROKOG.2.3. Meetings
An initial meeting of many study leaders at the VASCOG
2015 conference in Tokyo on 16 September 2015 supported
the official establishment of STROKOG. The proposed
structure of the consortium, including the functions of the
RSC and proposed projects were discussed. A second inter-
national meeting was held at VASCOG 2016 in Amsterdam
on 14 October 2016. Preliminary findings from the first proj-
ect were presented and potential projects were discussed.
2.4. Website
Awebsite that contains a description of STROKOG and
summaries of the member studies has been established
(https://cheba.unsw.edu.au/group/strokog). The website is
intended to serve as an avenue for presenting and preserving
STROKOG project protocols and results.
2.5. Ethics
The overall STROKOG project has been approved by
the Human Research Ethics Committee (HREC) of the
University of New South Wales (UNSW), Sydney (refer-
ence number: HC14359). Member studies are responsible
for obtaining approval (if necessary) from their local
institutional review board for the sharing of data.
Although de-identified data are not considered Protected
Health Information by the National Institutes of Health
of the United States, ethics review boards differ in
their approach to this matter. A protocol for the de-
identification of data has been developed. Additionally,each new project presented to STROKOG must be
approved by an institutional review board and the
HREC of UNSW informed about the project.
2.6. Research projects and data
The Sydney team will initiate the first project, collate
study data and conduct the initial data harmonization and
IPD meta-analyses across the different studies. STROKOG
will follow guidelines for rigorous and effective harmoni-
zation [58] as well as for IPD meta-analyses and reporting
[17,59]. Original data sets supplied by members and the
harmonized data sets, which will include derived data,
will be held by the Sydney team on a secure database at
the University of New South Wales. A STROKOG RSC
member can propose a research project, which need to
undergo an approval process by the RSC. If the
prospective proposer of a project is not a member of the
RSC or affiliated with a member study, the proposal can
still go ahead if it is sponsored by a member of the RSC.
A student may similarly request data for a research
project if sponsored by a member of the RSC. Once
approved, the proposer will be advised to form a Work
Group for the specific project, with a clearly identified
project leader. Other members of the consortium may
volunteer to be part of the Work Group if they have a
clear interest and expertise in the research project. The
Work Group will address and be responsible for the
planning, analysis, and publication of the approved
project. Data held by STROKOG will be released to the
Work Group; newly joined and existing member studies
will be requested to provide additional de-identified data.
Each cohort can opt-in or opt-out of participation; opting-
in represents a commitment to collaborate on the project.
The central STROKOG data repository at UNSW, Sydney,
will hold a copy of the data sets used for each project. The
STROKOG data will not be used or accessed for any pur-
pose other than contributing to an approved STROKOG
project.3. Discussion
3.1. Challenges
Large international consortia face general challenges that
include efficient communication among personnel involved
with studies across different countries and a need for addi-
tional funding to enable the further use of previously
collected data. Such challenges have been previously
described by other consortia (e.g., by CHARGE [60]).
Challengesmore specific toSTROKOGare those associated
with data harmonization, many of which have also been previ-
ously described [61,62].Neuropsychological test data are likely
to be the most challenging set of data to be harmonized across
studies due to heterogeneity in test instruments, administration,
and criteria for defining impairment; however, the Sydney team
has had experience harmonizing large data sets from diverse
Table 1
STROKOG member studies
Study Country Period
Sample
size*
Follow-up
schedule
Cognitive
assessments
MRI
assessmentsy Dementia criteria Key reference(s)
Action on Secondary
Prevention
Interventions and
Rehabilitation in
Stroke (ASPIRE-S)z
Ireland 2011–2012 256 6m 6 mo No NA Mellon et al.
(2015) [19]
Bundang VCI cohort
(Bundang-VCI)
Korea 2007–
ongoing
918 3m, 1y,
2y, 3y;
ongoing
3 mo, 1 y,
2 y, 3 y;
ongoing
Initial, 1–3 y DSM-IV Lim et al.
(2014) [20]
Clinical Biological and
Pharmacological
Factors Influencing
Stroke Outcome
(BIOSTROKE)
France 2005–2015 477 3m, 5y 5 y Initial, 5 y NA Ducroquet et al.
(2013) [21]
Cognition and Affect
after Stroke:
Prospective
Evaluation of Risks
(CASPER)
Netherlands 2013–2016 250 3m, 9m, 15m 3 mo, 9 mo,
15 mo
3 mo DSM-V, NINCDS-
ADRDA, NINDS-
AIREN
Douven et al.
(2016) [22]
Cognition and
Neocortical Volume
After Stroke
(CANVAS)
Australia 2014–2018 135 1m, 3m,
1y, 3y
3 mo, 1 y, 3 y Initial, 3 mo,
1 y, 3 y
DSM,
NINDS-
AIREN
Brodtmann et al.
(2014) [23]
Cognitive Function
After Stroke
(CogFAST-UK)
UK 2002–2012 355 3m; 1–8y
(annually)
3 mo; 1–8 y
(annually)
3 mo, 2 y Yes Allan et al.
(2011) [12]
Cognitive Function
After Stroke Nigeria
(CogFAST-Nigeria)
Nigeria 2010–
ongoing
217 3m 3 mo 3 mo
(small
subset only)
DSM-IV,
AHA/ASA
Akinyemi et al.
(2014) [24]
Cognitive Outcome
After Stroke
(COAST)
Singapore 2009–2017 400
(planned)
3–6m, 1y,
3–4y, 5y,
6y, 7y
3–6 mo, 1 y,
3–4 y, 5 y,
6 y, 7 y
Initial (small
subset only)
DSM-IV Dong et al.
(2012) [25]
Cracow Stroke
Database (Cracow)
Poland 2000–2001 250 3m, 12m 3 mo, 12 mo No DSM-IV Klimkowicz et al.
(2004; 2006)
[26,27]
Determinants of
Dementia After
Stroke
(DEDEMAS)
Germany 2011–2019 600
(planned)
3m, 6m,
1y, 2y, 3y,
4y, 5y
6 mo, 1 y,
3 y, 5 y;
(TICS
only: 3 mo,
2 y, 4 y)
Initial, 6 mo;
3 y, 5 y
DSM-V Wollenweber et al.
(2013) [28]
Durban Stroke Data
Bank (DSDB)
South Africa 1992–1998 1000 3m, 6m, 12m Initial, 3, 6,
13 mo
Initial DSM-IV Hoffmann (1998;
2001) [29,30]
Epidemiologic study of
the risk of dementia
after stroke (Epi
USA)
USA 1988–1999 585 Initial,
3m–10 y
(annually)
3 mo–10 y
(annually)
No Modified
DSM-III-R
Desmond et al.
(2000, 2002)
[7,31]
G€oteborg 70 1 Stroke
Study (G€oteborg
Neuro701)
Sweden 1993–1994 243 3m, 12m,
18m
18 mo Subset DSM-III-R Linden et al.
(2004; 2007)
[32,33]
Groupe de Reflexion
pour l’Evaluation
COGnitive
VASCulaire study
(GRECOG-VASC)x
France 2010–2015 360 6m 6 mo 6 mo VASCOG Godefroy et al.
(2012) [34]
Helsinki Stroke Aging
Memory (SAM)
Finland 1993–2015 486 3m, 15m,
21y
3 mo Initial DSM Jokinen et al.
(2015) [35];
Oksala et al.
(2009) [36]
(Continued )
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Table 1
STROKOG member studies (Continued )
Study Country Period
Sample
size*
Follow-up
schedule
Cognitive
assessments
MRI
assessmentsy Dementia criteria Key reference(s)
Maastricht Cognitive
Disorders After
Stroke (CODAS)
Netherlands 2000–2003 194 1m, 6m,
1y, 2y
1 mo, 6 mo,
1 y, 2 y
No DSM-III,
DSM-III-R,
DSM-IV, ICD-10,
NINDS-AIREN,
ADDTC
Rasquin et al.
(2005) [37]
Mild Stroke Study II
(MSS–II)
UK 2010–2015 264 1–3m,
1y, 3y
1–3 mo Initial,
1–3 mo, 1 y
ACER; MoCA
equivalent;
NART
Heye et al. (2015;
2016) [38,39],
Valdes
Hernanadez
et al. (2015)
[40]
Korean-Vascular
Cognitive
Impairment
Harmonization
Standards Study
(K-VCIHS)
Korea 2007–2008 620 3m 3 mo Initial DSM-IV Yu et al.
(2013) [41]
North East Melbourne
Stroke Incidence
Study (NEMESIS)
Australia 1998–2003 99 3m, 1y, 2y 3 mo, 1 y,
2 y
No Yes Srikanth et al.
(2003; 2004;
2006) [42–44]
National Neuroscience
Institute study (NNI
Singapore)
Singapore 2011–2017 506 3–6m, 1y
up to 5y
3–6 mo,
1 y up
to 5 y
Initial Yes Kandiah et al.
(2011; 2014,
2016) [45–47]
Prognosis of
Intracerebral
Hemorrhage
(PITCH)
France 2004–
ongoing
562 6 mo, 1 y,
2 y, 3 y,
4.5 y, 6 y,
8 y, 10 y
1 y, 2 y, 3 y,
4.5 y, 6 y,
8 y, 10 y
Initial, 6 mo;
1 y, 2 y, 3 y,
4.5 y, 6 y,
8 y, 10 y
Yes Cordonnier et al.
(2010) [48];
Moulin et al.
(2016) [49]
Prospective Study of
Pravastatin in the
Elderly at Risk
(PROSPER)k
Scotland,
Ireland,
Netherlands
1997–2001 649 9 mo, 1.5 y,
2.5 y, up
to 3 y
Initial, 9 mo,
1.5 y, 2.5 y,
study end
Initial,
study end
NA Shepherd et al.
(2002) [50]
Stroke Registry
Investigating
Cognitive Decline
(STRIDE)
Hong Kong 2009–2015 1013 3–6 mo, 1 y,
2 y, 3 y,
4 y, 5 y
3–6 mo Initial DSM-IV Yang et al. (2015)
[51]; Liu et al.
(2015) [52];
Wang et al.
(2015a, 2015b)
[53,54];
Mok et al.
(2016) [55]
Study of Factors
Influencing Post-
Stroke Dementia
(STROKDEM)
France 2011–2018 1100
(planned)
6 mo, 1 y,
3 y, 5 y
6 mo, 1 y,
3 y, 5 y
Initial, 6 mo,
3 y, 5 y
Yes NA
Sydney Stroke Study
(SSS)
Australia 1997–2005 351 3–6 mo, 1 y,
3 y, 5 y
3–6 mo,
1 y, 3 y, 5 y
3–6 mo, 1 y,
3 y, 5 y
Consensus
diagnosis
Sachdev et al.
(2004; 2014)
[56,57]
Abbreviations: m, month after index stroke; y, years after index stroke; ACER, Addenbrooke’s Cognitive Examination; ADDTC, Alzheimer’s Disease Diag-
nostic and Treatment Centers; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD-10, International Statistical Classification of Diseases, 10th
Revision; MoCA, TheMontreal Cognitive Assessment; NART, National Adult Reading Test performance in established dementia; NINCDS-ADRDA, National
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; NINDS-AIREN, National
Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; TICS, Telephone Interview
for Cognitive Status; VASCOG, International Society for Vascular Behavioral and Cognitive Disorders.
*Sample size denotes enrollment number (not follow-up) and does not include healthy control subjects. The studies which recruited control subjects were:
CANVAS (n 5 40), CogFAST-Nigeria (n 5 74), Epi USA (n 5 249), NEMESIS (n 5 99), PROSPER and SSS (n 5 129).
ySome studies also obtained PET scans from a subgroup of their participants: GRECOG-VASC (amyloid for 100 patients with poststroke cognitive deficit),
STROKDEM (at 1 year), DEDEMAS (amyloid/FDG for incident dementia cases), CANVAS (amyloid at 3 years), STRIDE (PiB, n5 50) and DSDB (SPECT,
n 5 36).
zASPIRE-S is an unofficial member that is planning to obtain participants’ permission to share data outside of Ireland before signing the MoU.
xFor the GRECOG-VASC study, only the 200 first patients from the Amiens center are included for STROKOG and the VASCOG criteria was used except for
the threshold of cognitive impairment which was set at the 5th percentile.
kPROSPER shares data at the summary level and not individual participant data.
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Table 2
Cognitive measures used by the STROKOG member studies to diagnose dementia
Study
Cognitive domain
Attention/processing
speed Memory Language
Construction
(visuospatial)
Executive function/
abstract reasoning
ASPIRE-S* NA NA NA NA NA
BIOSTROKE - Trail Making Test A
- Zazzo Test
- Digit symbol coding
- Bell’s Test
- FCSRT - Verbal fluency,
category
- Token Test
- VOSP
- Rey Complex
Figure Test: Copy
- Praxis score
- Trail Making Test B
- Verbal fluency, letter
- Stroop Test
Bundang-VCI - Trail Making Test A
- Digit symbol coding
- Seoul Verbal
Learning Test
- Boston Naming Test
- Verbal fluency,
category (animals)
- Rey Complex
Figure Test: Copy
- Trail Making Test B
- COWAT
CASPER - Trail Making Test A
- Digit Span Forward
- Digit Symbol Coding
- Start Cancellation
Task
- RAVLT (15-Word,
Dutch)
- Boston Naming Test
- Verbal fluency,
category (animals
and professions)
- Clock-drawing - Trail Making Test B
- Digit Span backward
- BADS Zoo map and
key search
CANVAS - Trail Making Test A
- Digit Span Forward
- Symbol Digit Mo-
dalities Test
- Cogstate Detection
Test and Identifica-
tion Test
- Star Cancellation
Task
- Hopkins Verbal
Learning Test
- Rey Complex
Figure Test: Recall
- Boston Naming Test
- Verbal fluency,
category (animals)
- Token Test
- Clock-Drawing Test
- Rey Complex
Figure Test: Copy
- Trail Making Test B
- Verbal fluency, letter
(FAS)
- Cogstate One-Back
Test
CogFAST-UK - Trail Making Test A
- Simple Reaction
Time
- Choice Reaction
Time
- Number Vigilance
task
- Digit Span forward
- Word-List Memory
- Rivermead
Behavioral
Memory Test
- Boston Naming Test
- Verbal fluency,
category (animals)
- Token Test
- Clock-Drawing Test
- Rey Complex
Figure Test: Copy
- Verbal fluency, letter
(FAS)
- Verbal Reasoning
- Visual Reasoning
- Trail Making Test B
- Digit Span backward
- Stroop Test
CogFAST-
Nigeria
- Choice Reaction
Time
- Word-List Learning
Test (10-item)
- Delayed recall of
stick design
- Boston Naming Test
- Verbal fluency,
category (animals)
- Token Test
- Stick Design Test - Verbal fluency, letter
(FAS)
- Verbal Reasoning
- Visual Reasoning
COAST - Digit Span Forward
- Visual Memory Span
Forward
- Auditory Detection
Test
- Symbol Digit Mo-
dalities Test
- Digit cancellation
task
- Word-List Recall
- Story Recall
- Picture Recall (im-
mediate and delayed
recall, and
recognition)
- Visual Reproduction
(immediate and
delayed recall, and
recognition)
- Boston Naming Test
- Verbal fluency,
category (animals,
food)
- Clock-Drawing Test
- Block Design
- Visual reproduction
copy
- Digit Span backward
- Visual memory span
backward
- Frontal Assessment
Battery
- Maze task
Cracowy NA NA NA NA NA
DEDEMAS - Trail Making Test A
- Digit Symbol Coding
- Word-List Memory
and Recall
- Discriminability
- Constructional
praxis (recall and
savings)
- FCSRT
- Boston Naming Test
- Verbal fluency,
category (animals)
- CERAD copy visual
construction
- Rey Complex
Figure Test: Copy
- Trail Making Test B
- Verbal fluency, letter
(S-words)
- Stroop Test
DSDB - Trail Making Test A - RAVLT - Boston Naming Test - Rey Complex
Figure Test: Copy
- Trial Making Test B
- Luria’s tests
- Wisconsin Card
Sorting Test
- Verbal fluency, letter
(FAS)
(Continued )
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Table 2
Cognitive measures used by the STROKOG member studies to diagnose dementia (Continued )
Study
Cognitive domain
Attention/processing
speed Memory Language
Construction
(visuospatial)
Executive function/
abstract reasoning
Epi USA - Target finding for
shapes and letters
- Selective Reminding
Test
- Benton Recognition
Test
- Boston Naming Test
- Verbal fluency,
category
- Complex Ideation
and Repetition sub-
tests of BDAE
- Copying geometric
figures
- Benton Matching
Test
- Similarities subtest
- Identities and
oddities
- Verbal fluency, letter
G€oteborg
Neuro701*
NA NA NA NA NA
GRECOG-
VASC
- Trail Making Test A
- Digit Symbol Coding
- Simple Reaction
Time
- Digit Tapping
- Albert cancellation
test
- FCSRT
- Door Visual Recog-
nition Test
- Rey Complex
Figure Test: Recall
- Boston Naming Test
- Verbal fluency,
category (animals)
- Rey Complex
Figure Test: Copy
- Trail Making Test B
- Verbal fluency, letter
(PVR)
- Strategic index
(FCSRT)
- Inventory of
Behavioral
Dysexecutive
Disorders
SAM - Trail Making Test A
- Stroop color naming
- Digit Span Forward
- Bell’s Test
- Logical memory
- Visual Reproduction
- Fuld Object Memory
Evaluation
- Boston Naming Test
- Verbal fluency,
category (animals)
- Token Test
- Boston Diagnostic
Aphasia Exam
(overall speech
evaluation)
- Reading, writing,
arithmetic operations
- Block Design
- Figure copying test
- Clock-Drawing Test
- Poppelreuter
- Trail Making Test B
- Digit Span backward
- Verbal fluency,
letter (K)
- Stroop Test
- Wisconsin Card
Sorting Test
- Similarities
- Comprehension
CODAS - Concept Shifting
Test Parts A and B
- Letter Digit
Substitution Test
- Stroop color naming
and reading test
- RAVLT (15-Word,
Dutch)
- Verbal fluency,
category (animals,
professions)
- GIT Vocabulary
- Clock drawing,
house drawing,
pentagons, spiral
(CAMCOG)
- GIT Mental Rotation
- Concept Shifting
Test Part C
- GIT Analogies
- Stroop Test
MSS–II* NA NA NA NA NA
K-VCIHS - Trail Making Test A
- Digit Symbol Coding
- Seoul Verbal
Learning Test
- Boston Naming Test
- Verbal fluency,
category (animals)
- Rey Complex
Figure Test: Copy
- Trail Making Test B
- COWAT
NEMESIS - KSNAP Mental
Status
- Digit Span Forward
- Digit Symbol Coding
- KSNAP Number
Recall
- Rivermead
Behavioral Memory
Test
- RAVLT
- Rey Complex
Figure Test: Recall
- Rey Complex
Figure Test: Copy
- Picture Completion
- Block Design
- KSNAP Gestalt
closure
- KSNAP 4 letter word
test
- Similarities
- Digit Span backward
- Verbal fluency, letter
(FAS)
NNI
Singapore
- Digit Span Forward - Word Recall - Verbal fluency,
category (animals)
- Clock drawing
(Sutherland)
- Digit span backward
- Frontal assessment
battery
PITCH - Trail Making Test A
- Digit Span Forward
- FCSRT
- Rey Complex
Figure Test: Recall
- Verbal fluency,
category
- Token Test
- Rey Complex
Figure Test: Copy
- Praxis score
- Trail Making Test B
- Verbal fluency, letter
- Card Sorting Test
- Digit Span backward
- Stroop Test
PROSPER - Letter Digit Substi-
tution Test
- Picture Learning
test: immediate and
delayed memory
- Doors and People
test
- Stroop Test
STRIDE* NA NA NA NA NA
(Continued )
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Table 2
Cognitive measures used by the STROKOG member studies to diagnose dementia (Continued )
Study
Cognitive domain
Attention/processing
speed Memory Language
Construction
(visuospatial)
Executive function/
abstract reasoning
STROKDEM - Trail Making Test A
- Zazzo Test
- Digit Symbol Coding
- Bell’s Test
- FCSRT - Verbal fluency,
category
- Token Test
- VOSP
- Rey Complex
Figure Test: Copy
- Praxis score
- Trail Making Test B
- Verbal fluency, letter
- Stroop Test
SSS - Trail Making Test A
- Digit Span Forward
- Mental Control
- Symbol Digit Mo-
dalities Test
- Choice Reaction
Time
- Logical Memory
I & II
- Verbal memory
recall
- Visual Reproduction
I & II
- Visual memory
recall
- Boston Naming Test
- Sentence repetition
- Verbal fluency,
category (animals)
- Token Test
- Block design
- Simple copying
- Picture completion
- Trail Making Test B
- Digit Span backward
- Similarities
- Identities and
oddities
- COWAT
Abbreviations: BADS, behavioral assessment of the dysexecutive syndrome; BDAE, Boston Diagnostic Aphasia Examination; CAMCOG, Cambridge
Cognitive Examination; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; COWAT, Controlled Oral Word Association Test; CSID, Com-
munity Screening Interview for Dementia; FCSRT, Free and Cued Selective Reminding Test; GIT, Groninger Intelligence Test; HCFD, higher cortical function
deficits; KSNAP, Kaufman short neuropsychological assessment procedure; RAVLT, ReyAuditory Verbal Learning Test; VOSP, visual object and space percep-
tion battery.
NOTE. The assignment of a neuropsychological test to a particular cognitive domain is based on convention and previous work such as for COSMIC [17] and
may not be how a study has assigned the test.
*ASPIRE-S, MSS-II, G€oteborg Neuro701 and STRIDE did not conduct detailed neuropsychological test batteries, instead, the following tests were used to
diagnose dementia in each study: ASPIRE-S: MoCA (The Montreal Cognitive Assessment); G€oteborg Neuro701: Cognitive symptom ratings and items from
ADAS-Cog (The Alzheimer’s Disease Assessment Scale-Cognition); MSS-II: NART (National Adult Reading Test performance in established dementia) was
conducted for pre-morbid cognitive ability; specific additional tests for current cognition were not performed outside of ACER (Addenbrooke’s Cognitive Ex-
amination) and MOCA (equivalent); STRIDE: The Mini–Mental Status Examination (MMSE) and MoCA.
yCracow study conducted neuropsychological tests under the five domains but these data were lost and not available.
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exists much heterogeneity in measurement instruments used
by different studies. Even when studies have used similar tests,
different versions of tests were used, and tests might have been
administered in nonstandardways. Owing to differences in cul-
ture and language, questions and responses may have been
worded differently. There is no consensus on how each neuro-
psychological test should be allocated to a specific cognitive
domain as such tests are generallymultifactorial. Table 2 shows
the list of tests used in the studies under five cognitive domains;
each test was assigned to a cognitive domain based on
convention and previous work such as for COSMIC [63].
Demographic effects such as age, gender, and education need
to be accounted for. Furthermore, adequate normative data
may or may not be available in all regions or for all ethnocul-
tural groups; not all studies included nondemented stroke-free
controlswhose test scoresmaybeused to derive adjusted scores
and to define cognitive impairment.3.2. Advantages
The benefits of being able to reuse, combine, and compare
data frommultiple cohorts are obvious, and this approach has
been recommended by the Lancet REWARDCampaign [64].
Cohort studies focused on stroke and cognition are expen-
sive, labor-intensive, and very demanding of researchers’
and participants’ time. Multiple factors may limit the studysample size and duration. There already exists a wealth of
data from previous or current studies that are underutilized
and can be put to further use. Standard meta-analysis is one
way of analyzing the combined cohorts of existing studies,
but it is limited to published results and specific research
questions. STROKOG’s approach in harmonizing individual
participant data from various studies is an economical use of
previously collected data to explore both existing and novel
research questions. According to the Cochrane Methods
group, IPDmeta-analyses are considered the “gold standard”
of systematic review [65]. In IPD meta-analyses, individual
participant data from all studies can be modeled simulta-
neously while accounting for the clustering of participants
within studies [17]. It allows detailed participant-level explo-
ration of cognitive disorders in relation to the individuals’
characteristics. Additionally, statistical analysis can be stan-
dardized across studies where more appropriate or advanced
methods can be used; baseline and potential confounding fac-
tors can be adjusted for consistency across studies; results for
missing or poorly acquired outcomes can be reported,
thereby reducing bias within study reporting; results for spe-
cific subgroups of participants can be obtained across studies;
unpublished data can be included, thereby addressing publi-
cation bias [17]. Having access to a rich collection of individ-
ual participant-level data from international studies,
STROKOG is in a unique position to apply IPD meta-
analyses techniques and fully explore and examine patient
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to facilitating a better understanding of various aspects of
post-stroke cognitive impairment.
A consortium such as STROKOG has the added benefit of
informingnew researchers of the need to standardize theirmea-
sures andmethods so that they are in stepwith other researchers
in the same field. This is particularly important for stroke and
dementia, as many researchers from low and middle income
countries have recently become interested in this topic and
are mounting studies that would benefit from comparability
with existing studies. New studies therefore would have the
benefit of validated measures and better comparability.
There is also the potential for the STROKOG database to
be made available to nonconsortium researchers following
consortium-based publications and with the approval of
the RSC and the ethics review board. The scientific benefits
of making large databases available to researchers world-
wide have been demonstrated by the more than 250 publica-
tions that have resulted from the sharing of ADNI
(Alzheimer’s Disease Neuroimaging Initiative) data [66].
The research community that STROKOG proposes to
create is likely to pay other dividends. It is expected that the
productivity of the group will increase over time in quality
and quantity; junior researchers will be supported, new ideas
and lines of investigationwill be generated and scientific inter-
change and collaboration will be facilitated. The benefits will
therefore extend beyond the harmonizing and pooling of data.3.3. Specific projects
The first project aims to describe the prevalence and profile
of poststroke cognitive impairment, measured between 1 and
6months after a stroke or TIA, in diverse geographical and eth-
nocultural settings as represented by the STROKOG member
cohorts. The project is currently underway and is being coordi-
nated by the Sydney team.A project proposal was approved by
the RSC, and the following data are currently being requested:
1. Demographics.
2. Stroke-related variables.
3. Medical history/risk factors.
4. Functional assessments and screening tests.
5. Neuropsychological test data.
6. Neurological assessments and psychiatric examina-
tions.
7. Cognitive disorder diagnosis.
A number of projects utilizing STROKOG data have been
proposed for the future, and they aim to examine across
STROKOG cohorts
1. Rates of cognitive decline in post-stroke patients.
2. Determinants of cognitive impairment.
3. Determinants of cognitive decline.
4. Effect of methodologic differences in the collection
and interpretation of cognitive data on the estimation
of prevalence of cognitive deficit.5. Specific risk factors such as atrial fibrillation, conges-
tive heart failure, diabetes, and homocysteine.
6. Depression and apathy in relation to cerebrovascular
disease.
7. Relative contributions of Alzheimer’s and vascular pa-
thologies to dementia.
8. Precise and reliable quantitation and localization of
white-matter hyperintensities, microbleeds, lacunes
and micro-infarcts and examination of their relation-
ship to cognition.
While many of the existing member studies have relevant
data to contribute to the more general topics (such as 1 to 4
noted above), the more specific topics (5 to 8) will be best
addressed by growing the STROKOG membership base.
Therefore, we encourage any investigators with a study
meeting the eligibility criteria to contact STROKOG and
become a member of the consortium.4. Conclusion
STROKOG is a truly international consortium of studies
with a focus on cognitive disorders associated with cerebro-
vascular disease. It has the potential to transform our under-
standing of the epidemiology and natural course of VCD and
have a worldwide impact on promoting better cognitive out-
comes in the setting of cerebrovascular disease.
Acknowledgments
ASPIRE-S: The authors acknowledge the ASPIRE-S Steering
Group members: Professor HannahMcGee, Royal College of
Surgeons in Ireland; Professor Emer Shelley, Royal College
of Surgeons in Ireland; Professor Peter Kelly, Mater Miseri-
cordiae University Hospital, Dublin; Dr Eamon Dolan, Con-
nolly Hospital, Dublin. BIOSTROKE and STROKDEM:
French Health Ministery, the Vascog FHU, the ‘Fondation
Coeur et Arteres’. CANVAS: CANVAS researchers wish to
acknowledge support from the NHMRC (APP1020526 and
APP1094974), Sidney and Fiona Myer Foundation and the
Collie Trust. CASPER: The CASPER project team consists
of Ms. Syenna Schievink, Ms Elles Douven, Dr Sebastian
K€ohler, Dr Pauline Aalten, Dr Julie Staals, Professor Robert
van Oostenbrugge, and Professor Frans Verhey. COAST:
The authors thank all participants for their involvement, the
research team from NUHS Memory Ageing and Cognition
Centre for data collection. CogFAST-UK: The authors are
very grateful to the patients, families, clinical staff and previ-
ous co-investigators for their co-operation and help with the
execution of the study. CogFAST-Nigeria: The authors are
very grateful to the patients, families and clinical staff for
their co-operation and help with the execution of the study.
DSDB: The Durban Cerebrovascular Group, Department of
Surgery and Neurology, University of Kwa-Zulu Natal and
Entabeni Hospital Stroke Center, Durban, South Africa.
GRECOG-VASC: French Health Ministry. MSS-II: MMS2
acknowledges the Wellcome Trust, Row Fogo Charitable
P.S. Sachdev et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 11-23 21Trust; Fergus Doubal is supported by the Stroke Association
and Garfield Weston Foundation. NEMESIS: The National
Health and Medical Research Council of Australia
(NHMRC). PITCH: Charlotte Cordonnier is a member of
the Institut Universitaire de France.
The funding provided for the study is as follows: STRO-
KOG: The Dementia Momentum fund from the Centre of
Healthy Brain Ageing (CHeBA), UNSW Medicine, Uni-
versity of New South Wales and Vincent Fairfax Family
Foundation. ASPIRE-S: Irish Health Research Board
(HRB; grant number 1404/7400). CASPER and CODAS:
Maastricht University, Health Foundation Limburg, and
the Adriana van Rinsum-Ponsen Stichting. The sponsors
had no role in the design of the study and collection, anal-
ysis, and interpretation of data, and in writing the manu-
script. COAST: National Medical Research Council
(NMRC/CG/NUHS/2010) and National University Health
System National Clinician Scientist Program (NUHS
NCSP). Y.D. was a recipient of the NUHS NCSP award
during this study. CogFAST-UK: R.N.K. was supported
by grants from the Newcastle Centre for Brain Ageing
and Vitality (BBSRC, EPSRC, ESRC and MRC, LLHW;
G0700718). The original CogFAST-UK research pro-
grammes were supported by the UK Medical Research
Council (MRC, G0500247 and G9817621). CogFAST-
Nigeria: R.O.A. was supported by a fellowship from the In-
ternational Brain Research Organization (IBRO) Paris,
France and by an ORS Award from the Newcastle Univer-
sity, UK. DEDEMAS: Vascular Dementia Research Foun-
dation. Flutemetamol (18F) was provided by GE
Healthcare. Epi USA: National Institutes of Health (grants
R01-NS26179 and P01-AG07232). GRECOG-VASC:
French Health Ministry. MSS-II: Wellcome Trust number
WT088134/Z/09/A.Row Fogo Trust. NEMESIS: NHMRC,
Victorian Health Promotion Foundation, Austin Hospital
Medical Research Foundation, Perpetual Trustees, National
Stroke Foundation, Foundation for High Blood Pressure
Research. NNI: National Neuroscience Institute,
Singapore. PROSPER: The original PROSPER clinical
trial was founded by an investigator initiated grant from
Bristol-Myers Squibb, USA. However, the company had
no involvement in the formulation of hypotheses, analysis
of the data or in any aspect of the preparation of this manu-
script. SAM: Helsinki University Central Hospital, Hel-
sinki. STRIDE: Health and Health Services Research
Fund (0708041) of the Food and Health Bureau of the Gov-
ernment of the HKSAR, the Lui Che Woo Institute of Inno-
vative Medicine, and Therese Pei Fong Chow Research
Centre for Prevention of Dementia (in memory of Donald
H K Chow). SSS: National Health and Medical Research
Council.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.dadm.2016.10.006.RESEARCH IN CONTEXT
1. Systematic review: The authors performed a review
of published studies of poststroke cognitive impair-
ment and dementia using PubMed and invited all
eligible studies to participate. Unpublished studies
were identified through correspondence with mem-
bers of the Society for Vascular Cognitive and
Behavioral Disorders (VASCOG).
2. Interpretation: The STROKOG consortium brings
together international longitudinal cohort studies of
cognitive decline and dementia following stroke or
TIA. By harmonizing data and conducting individual
participant meta-analyses, STROKOG aims to better
understand the determinants and manifestations of
vascular contributions to cognitive disorders and
help improve the diagnosis and treatment of vascular
cognitive disorders.
3. Future directions: STROKOG will conduct individ-
ual projects investigating research topics such as
the prevalence of VCD, rates of cognitive decline,
determinants of cognitive impairment and the fre-
quency of depression in relation to cerebrovascular
disease. STROKOG invites other longitudinal
studies on stroke/TIA patients and cognitive impair-
ment to join, contribute to the database and partici-
pate in collaborative research.References
[1] Roman GC. Managing Vascular Dementia. London: Science Press;
2003.
[2] Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A,
Breteler MM, et al. Prevalence of dementia and major subtypes in Eu-
rope: A collaborative study of population-based cohorts. Neurologic
Diseases in the Elderly Research Group. Neurology 2000;54:S4–9.
[3] Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C,
McDowell I. Prevalence and outcomes of vascular cognitive impair-
ment. Neurology 2000;54:447–51.
[4] Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R,
Kaste M. Clinical determinants of poststroke dementia. Stroke 1998;
29:75–81.
[5] Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JCL,
Berman K, et al. Clinical determinants of dementia and mild cognitive
impairment following ischaemic stroke: the Sydney Stroke Study. De-
ment Geriatr Cogn Disord 2006;21:275–83.
[6] Makin S, Turpin S, Dennis M, Wardlaw J. Cognitive impairment after
lacunar stroke: systematic review and meta-analysis of incidence,
prevalence and comparison with other stroke sub-types. J Neurol Neu-
rosurg Psychiatry 2013;84:893–900.
[7] Desmond DW,Moroney JT, PaikMC, SanoM,Mohr JP, Aboumatar S,
et al. Frequency and clinical determinants of dementia after ischemic
stroke. Neurology 2000;54:1124–31.
P.S. Sachdev et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 11-2322[8] Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors asso-
ciated with pre-stroke and post-stroke dementia: a systematic review
and meta-analysis. Lancet Neurol 2009;8:1006–18.
[9] Savva GM, Stephan BC, the Alzheimer’s Society Vascular Dementia
Systematic Review Group. Epidemiological studies of the effect of
stroke on incident dementia: A systematic review. Stroke 2010;
41:e41–6.
[10] Sposato LA, Kapral MK, Fang J, Gill SS, Hackam DG, Cipriano LE,
et al. Declining incidence of stroke and dementia: coincidence or pre-
vention opportunity? JAMA Neurol 2015;72:1529–31.
[11] Pendlebury ST. Stroke-related dementia: rates, risk factors and impli-
cations for future research. Maturitas 2009;64:165–71.
[12] Allan L, Rowan EN, Firbank MJ, Thomas AJ, Parry SW,
Polvikoski TM, et al. Long term incidence of dementia, predictors
of mortality and pathological diagnosis in older stroke survivors. Brain
2011;134:3713–24.
[13] Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al.
Dementia after stroke: the FraminghamStudy. Stroke 2004;35:1264–8.
[14] Gottesman RF, Hills AE. Predictors and assessment of cognitive
dysfunction resulting from ischaemic stroke. Lancet Neurol 2010;
9:895–905.
[15] Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM,
Iadecola C, et al. Vascular contributions to cognitive impairment and de-
mentia: a statement for healthcare professionals from the american heart
association/american stroke association. Stroke 2011;42:2672–713.
[16] METACOHORTS Consortium. METACOHORTS for the study of
vascular disease and its contribution to cognitive decline and neurode-
generation: An initiative of the Joint Programme for Neurodegenera-
tive Disease Research. Alzheimers Dement 2016; http://dx.doi.org/
10.1016/j.jalz.2016.06.004 [Epub ahead of print].
[17] Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual
participant data: rationale, conduct, and reporting. BMJ 2010;
340:521–5.
[18] Lyman GH, Kuderer NM. The strengths and limitations of meta-
analyses based on aggregate data. BMCMedResMethodol 2005;5:14.
[19] Mellon L, Brewer L, Hall P, Horgan F, Williams D, Hickey A, et al.
Cognitive impairment six months after ischaemic stroke: a profile
from the ASPIRE-S study. BMC Neurol 2015;15.
[20] Lim JS, Kim N, Jang MU, Han MK, Kim S, Baek MJ, et al. Cortical
hubs and subcortical cholinergic pathways as neural substrates of post-
stroke dementia. Stroke 2014;45:1069–76.
[21] DucroquetA,LeysD, SaabiAA,RichardF,CordonnierC,GirotM,et al.
Influence of chronic ethanol consumption on the neurological severity
in patients with acute cerebral ischemia. Stroke 2013;44:2324–6.
[22] Douven E, Schievink SH, Verhey FR, van Oostenbrugge JR, Aalten P,
Staals J, et al. The Cognition and Affect after Stroke – a Prospective
Evaluation of Risks (CASPER) study: rationale and design. BMC
Neurol 2016;16:65.
[23] Brodtmann A, Werden E, Pardoe H, Li Q, Jackson G, Cowie T, et al.
Charting cognitive and volumetric trajectories after stroke: protocol
for the Cognition And Neocortical Volume After Stroke (CANVAS)
study. Int J Stroke 2014;9:824–8.
[24] Akinyemi RO, Allan L, Owolabi MO, Akinyemi JO, Ogbole G,
Ajani A, et al. Profile and determinants of vascular cognitive impair-
ment in African stroke survivors: The CogFAST – Nigeria Study. J
Neurol Sci 2014;346:241–9.
[25] Dong Y, Venketasubramanian N, Poon-Lap Chan BP, Sharma VK,
Slavin MJ, Collinson SL, et al. Brief screening tests during acute
admission in patients with mild stroke are predictive of vascular cogni-
tive impairment 3-6 months after stroke. J Neurol Neurosurg Psychia-
try 2012;83:580–5.
[26] Klimkowicz A, Dziedzic T, Polczyk R, Pera J, S1owik A, Szczudlik A.
Factors associated with pre-stroke dementia: the cracow stroke data-
base. J Neurol 2004;251:599–603.
[27] Klimkowicz-Mrowiec A, Dziedzic T, S1owik A, Szczudlik A. Predic-
tors of poststroke dementia: results of a hospital-based study in Poland.
Dement Geriatr Cogn Disord 2006;21:328–34.[28] Wollenweber FA, Zietemann V, Rominger A, Opherk C, Bayer-
Karpinska A, Gschwendtner A. The Determinants of Dementia After
Stroke (DEDEMAS) Study: protocol and pilot data. Int J Stroke
2014;9:387–92.
[29] HoffmannM. Stroke in the young: The multiethnic prospective durban
stroke data bank results. J Stroke Cerebrovasc Dis 1998;7:404–13.
[30] HoffmannM. Higher cortical function deficits after stroke: an analysis
of 1,000 patients from a dedicated cognitive stroke registry. Neurore-
habil Neural Repair 2001;15:113–27.
[31] DesmondDW,Moroney JT, SanoM,SternY. Incidence of dementia after
ischemic stroke: results of a longitudinal study. Stroke2002;33:2254–60.
[32] Linden T, Skoog I, Fagerberg B, Steen B, Blomstrand C. Cognitive
impairment and dementia 20 months after stroke. Neuroepidemiology
2004;23:45–52.
[33] Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months
in elderly stroke patients: a case-control study. Stroke 2007;38:1860–3.
[34] Godefroy O, Leclercq C, Roussel M, Moroni C, Quaglino V,
Beaunieux H. French adaptation of the vascular cognitive impairment
harmonization standards: the GRECOG-VASC study. Int J Stroke
2012;7:362–3.
[35] Jokinen H, Melkas S, Ylikoski R, Pohjasvaara T, Kaste M,
Erkinjuntti T, et al. Post-stroke cognitive impairment is common
even after successful clinical recovery. Eur J Neurol 2015;
22:1288–94.
[36] Oksala N, Jokinen H, Melkas S, Oksala A, Pohjasvaara T, HietanenM,
et al. Cognitive impairment predicts poststroke death in long-term
follow up. J Neurol Neurosurg Psychiatry 2009;80:1230–5.
[37] Rasquin SM, Lodder J, Verhey FR. The effect of different diagnostic
criteria on the prevalence and incidence of post-stroke dementia. Neu-
roepidemiology 2005;24:189–95.
[38] Heye AK, Thrippleton MJ, Armitage PA, Valdes Hernandez Mdel C,
Makin SD, Glatz A, et al. Tracer kinetic modelling for DCE-MRI
quantification of subtle blood-brain barrier permeability. Neuroimage
2016;125:446–55.
[39] Heye AK, Thrippleton MJ, Chappell FM, Valdes Hernandez MD,
Armitage PA,Makin SD, et al. Blood pressure and sodium: association
with MRI markers in cerebral small vessel disease. J Cereb Blood
Flow Metab 2016;36:264–74.
[40] Valdes Hernandez Mdel C, Armitage PA, Thrippleton MJ,
Chappell F, Sandeman E, Mu~noz Maniega S, et al. Rationale, design
and methodology of the image analysis protocol for studies of
patients with cerebral small vessel disease and mild stroke. Brain Be-
hav 2015;5:e00415.
[41] Yu KH, Cho SJ, Oh MS, Jung S, Lee JH, Shin JH, et al. Cognitive
impairment evaluated with Vascular Cognitive Impairment Harmoni-
zation Standards in a multicenter prospective stroke cohort in Korea.
Stroke 2013;44:786–8.
[42] Srikanth VK, Quinn SJ, Donnan GA, Saling MM, Thrift AG. Long-
term cognitive transitions, rates of cognitive change, and predictors
of incident dementia in a population-based first-ever stroke cohort.
Stroke 2006;37:2479–83.
[43] Srikanth V, Anderson JF, Donnan GA, Saling MM, Didus E,
Alpitsis R, et al. Progressive dementia after first-ever stroke: a
community-based follow-up study. Neurology 2004;63:785–92.
[44] Srikanth VK, Thrift AG, Saling MM, Anderson JF, Dewey HM,
Macdonell RA. Increased risk of cognitive impairment 3 months after
mild tomoderate first-ever stroke: aCommunity-Based Prospective Study
of Nonaphasic English-Speaking Survivors. Stroke 2003;34:1136–43.
[45] Kandiah N, Wiryasaputra L, Narasimhalu K, Karandikar A,
Marmin M, Chua EV, et al. Frontal subcortical ischemia is crucial
for post stroke cognitive impairment. J Neurol Sci 2011;309:92–5.
[46] Kandiah N, Goh O, Mak E, Marmin M, Ng A. Carotid stenosis: A risk
factor for white-matter disease. J Stroke Cerebrovasc Dis 2014;
23:136–9.
[47] Kandiah N, Chander RJ, Lin XL, Ng A, Poh YY, Cheong CY, et al.
Cognitive impairment after mild stroke: Development and validation
of the SIGNAL2 Risk Score. J Alzheimers Dis 2016;49:1169–77.
P.S. Sachdev et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 11-23 23[48] Cordonnier C, Leys D, Dumont F, Deramecourt V, Bordet R,
Pasquier F, et al. What are the causes of pre-existing dementia
in patients with intracerebral haemorrhages? Brain 2010;
133:3281–9.
[49] Moulin S, Labreuche J, Bombois S, Rossi C, Boulouis G, Henon H,
et al. Dementia risk after spontaneous intracerebral haemorrhage: a
prospective cohort study. Lancet Neurol 2016;15:820–9.
[50] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM,
Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular
disease (PROSPER): a randomised controlled trial. Lancet 2002;
360:1623–30.
[51] Yang J, Wong A,Wang Z, LiuW, Au L, Xiong Y, et al. Risk factors for
incident dementia after stroke and transient ischemic attack. Alz-
heimers Dement 2015;11:16–23.
[52] Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, et al. Influence of
amyloid-b on cognitive decline after stroke/transient ischemic attack:
three-year longitudinal study. Stroke 2015;46:3074–80.
[53] Wang Z,WongA, LiuW, Yang J, ChuWC,Au L, et al. Cerebral micro-
bleeds and cognitive function in ischemic stroke or transient ischemic
attack patients. Dement Geriatr Cogn Disord 2015;40:130–6.
[54] Wang Z, Wong A, Liu W, Yang J, Chu WC, Au L, et al. Pulse pressure
and cognitive decline in stroke patients with white matter changes. J
Clin Hypertens (Greenwich) 2015;17:694–8.
[55] Mok VC, Lam BY, Wang Z, Liu W, Au L, Leung EY, et al. Delayed-
onset dementia after stroke or transient ischemic attack. Alzheimers
Dement 2016;12:1167–76.
[56] Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W,
et al. The neuropsychological profile of vascular cognitive impairment
in stroke and TIA patients. Neurology 2004;62:912–9.
[57] Sachdev PS, Lipnicki DM, Crawford JD, WenW, Brodaty H. Progres-
sion of cognitive impairment in stroke/TIA patients over 3 years. J
Neurol Neurosurg Psychiatry 2014;85:1324–30.[58] Fortier I, Raina P, Van den Heuvel ER, Griffith LE, Craig C, Saliba M,
et al. Maelstrom Research guidelines for rigorous retrospective data
harmonization. Int J Epidemiol 2016. pii: dyw075. [Epub ahead of print].
[59] Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC,
Stewart LA. Statistical analysis of individual participant data meta-
analyses: a comparison of methods and recommendations for practice.
PLoS One 2012;7:e46042.
[60] Psaty BM, O’Donnell CJ, Gudnason V, Lunetta KL, Folsom AR,
Rotter JI, et al. Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium: Design of prospective meta-
analyses of genome-wide association studies from five cohorts. Circ
Cardiovasc Genet 2009;2:73–80.
[61] Schaap LA, Peeters GM, Dennison EM, Zambon S, Nikolaus T, San-
chez-Martinez M, et al. European Project on OSteoArthritis (EPOSA):
methodological challenges in harmonization of existing data from five
European population-based cohorts on aging. BMC Musculoskelet
Disord 2011;12:272.
[62] Pluijm SM, Bardage C, Nikula S, Blumstein T, Jylha M, Minicuci N,
et al. A harmonized measure of activities of daily living was a reliable
and valid instrument for comparing disability in older people across
countries. J Clin Epidemiol 2005;58:1015–23.
[63] Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A,
Andrews G, et al. The prevalence of mild cognitive impairment in
diverse geographical and ethnocultural regions: The COSMIC Collab-
oration. PLoS One 2015;10:e0142388.
[64] REWARD. The Lancet. Available at: http://www.thelancet.com/
campaigns/efficiency/statement. Accessed June 01, 2016.
[65] CochraneMethods: IPDMeta-analysis.TheCochrane collaboration.Avail-
able at: http://methods.cochrane.org/ipdma/. Accessed August 22, 2016.
[66] Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alz-
heimer’s disease neuroimaging initiative. Alzheimers Dement 2012;
8:337–42.
